secwatch.observer — SEC 8-K summary
======================================

Issuer:     PTC THERAPEUTICS, INC. (PTCT)
CIK:        0001070081
Form:       8-K
Filed at:   2022-10-27T23:59:59+00:00
Accession:  0001070081-22-000038
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PTC Therapeutics Q3 revenue $217M (+57% YoY); raises DMD full-year guidance; secures $350M Blackstone financing
--------------------------------------------------------------------------------

- Q3 total revenue $217.1M (+57% YoY); net product revenue $134.2M, royalty and collaboration $82.9M.
- DMD franchise net product rev $131.4M (Translarna $76.6M, Emflaza $54.8M); full-year DMD guidance raised to $490-500M.
- Strategic financing from Blackstone: initial $350M at close, option for additional $650M low-cost, low-dilution capital.
- Net loss improved to $109.3M from $133.6M in Q3 2021; cash $288.4M as of Sep 30, 2022.
- Clinical: EMA submission for Translarna standard approval; FDA meeting for Translarna US NDA; Upstaza BLA expected H1 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1070081/000107008122000038/0001070081-22-000038-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1070081/000107008122000038/tmb-20221027x8k.htm
  HTML page:      https://secwatch.observer/filing/0001070081-22-000038

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer